ストックスクリーナーアプリを入手
128.34
0.12%
0.16
アフターアワーズ：
128.36
0.02
+0.02%
前日終値:
$128.18
開ける：
$128.18
24時間の取引高:
2.59M
Relative Volume:
1.01
時価総額：
$8.26B
収益：
$434.41M
当期純損益:
$-128.05M
株価収益率:
-60.82
EPS:
-2.11
ネットキャッシュフロー:
$-250.52M
1週間 パフォーマンス:
+0.06%
1か月 パフォーマンス:
+26.63%
6か月 パフォーマンス:
+47.15%
1年 パフォーマンス:
+17.55%
1日の値動き範囲:
$128.16
$128.52
1週間の範囲:
$128.06
$128.52
52週間の値動き範囲:
$73.04
$128.52
Blueprint Medicines Corp Stock (BPMC) Company Profile
名前
Blueprint Medicines Corp
セクター
電話
617-374-7580
住所
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
128.34 | 8.26B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-03-20 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-03-18 | 開始されました | Wolfe Research | Outperform |
| 2025-03-17 | 開始されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-14 | 開始されました | JP Morgan | Overweight |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-05-06 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 繰り返されました | Needham | Buy |
| 2023-07-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-11-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2022-07-08 | 開始されました | Oppenheimer | Outperform |
| 2022-06-27 | 開始されました | Wells Fargo | Underweight |
| 2022-06-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-06-01 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-01 | 開始されました | Citigroup | Neutral |
| 2022-02-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | アップグレード | Stifel | Hold → Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 再開されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-11-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-02 | ダウングレード | Jefferies | Buy → Hold |
| 2020-10-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Equal Weight |
| 2020-03-17 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-11-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-09-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 開始されました | Piper Jaffray | Neutral |
| 2019-08-15 | 再開されました | Raymond James | Mkt Perform |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-05-23 | 再開されました | Goldman | Buy |
| 2019-04-03 | 開始されました | Morgan Stanley | Overweight |
| 2018-09-25 | 開始されました | Leerink Partners | Outperform |
| 2017-12-11 | 繰り返されました | Goldman | Buy |
すべてを表示
Blueprint Medicines Corp (BPMC) 最新ニュース
Blueprint Medicines (BPMC) Downgraded by Wells Fargo Amid Acquis - GuruFocus
BPMC: Wells Fargo Downgrades Blueprint Medicines, Lowers Price Target | BPMC Stock News - GuruFocus
Sanofi, Blueprint Medicines filed HSR June 9 - MLex
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders - GlobeNewswire Inc.
Blueprint Medicines’ SWOT analysis: stock poised for growth amid Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Showcases Groundbreaking Data on Syst - GuruFocus
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PR Newswire
Blueprint Medicines Stock Experiences Wild Intraday Swing, Closes Flat Amid Strong Momentum - Daily Chhattisgarh News
Blueprint Medicines stock hits all-time high of $128.3 By Investing.com - Investing.com Canada
Blueprint Medicines stock hits all-time high of $128.3 - Investing.com
Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSN
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta - Benzinga
Blueprint Medicines (BPMC): Morgan Stanley Raises Price Target | BPMC Stock News - GuruFocus
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal - TradingView
Citigroup Upgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq
Sanofi to acquire Blueprint Medicines for about $9.1B - Drug Store News
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | - GuruFocus
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Sees Price Target Increase Amid Acquisition News | BPMC Stock News - GuruFocus
Sanofi to buy Blueprint Medicines for $9.1B - MSN
Blueprint Medicines (BPMC) Target Price Increased Following Acqu - GuruFocus
Blueprint Medicines (BPMC) Target Price Increased Following Acquisition News | BPMC Stock News - GuruFocus
Stephens & Co. Downgrades Blueprint Medicines (BPMC) to Equal Weight, Cuts PT - Insider Monkey
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform - Insider Monkey
Sanofi to Buy Blueprint for $9.1 Billion Equity Value - MSN
Nasdaq Today Blueprint Medicines Reclassified Kalkine - Kalkine Media
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly - GuruFocus
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly | BPMC Stock News - GuruFocus
Citi upgrades Blueprint Medicines stock rating after Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Sees Upgrade and Acquisition by Sanof - GuruFocus
Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition - MSN
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines CorporationBPMC - Business Wire
Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen - Insider Monkey
Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform - Insider Monkey
Blueprint Medicines (BPMC) Downgraded Following Acquisition News - GuruFocus
Blueprint Medicines (BPMC) Downgraded Following Acquisition News | BPMC Stock News - GuruFocus
Blueprint Medicines downgraded to Neutral from Buy at Guggenheim - TipRanks
Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132 - marketscreener.com
Sanofi to acquire Blueprint for up to $9.5B - Pharma Voice
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC S - GuruFocus
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Stephens & Co - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Wolfe Research | BPMC Stock News - GuruFocus
Wolfe Downgrades Blueprint Medicines to Peer Perform From Outperform - marketscreener.com
Blueprint Medicines (BPMC) Downgraded Following Acquisition Deal - GuruFocus
Stephens Downgrades Blueprint Medicines to Equalweight From Overweight, Adjusts PT to $135 From $150 - marketscreener.com
JPMorgan Downgrades Blueprint Medicines to Neutral From Overweight, Adjusts PT to $129 From $130 - marketscreener.com
Sanofi to acquire US biotech firm Blueprint for up to $9.5bn - World Pharmaceutical Frontiers
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Pr - GuruFocus
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Proposal | BPMC Stock News - GuruFocus
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition - Investing.com
Blueprint Medicines Corp (BPMC) 財務データ
収益
当期純利益
現金流量
EPS
Blueprint Medicines Corp (BPMC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
May 27 '25 |
Option Exercise |
36.05 |
5,000 |
180,250 |
151,630 |
| Albers Jeffrey W. | Director |
May 27 '25 |
Sale |
101.14 |
5,000 |
505,692 |
146,630 |
0.39%
0.42%
大文字化:
|
ボリューム (24 時間):